NCT05033522 2025-10-23
ALIVE
Mirror Biologics, Inc.
Phase 2/3 Suspended
Clinical Trials
60 trialsNCT03037437 2025-09-04
Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT01754987 2025-05-04
A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective
Thomas Jefferson University
Phase 1/2 Completed
NCT02716012 2025-03-10
OUTREACH
Mina Alpha Limited
Phase 1 Unknown
NCT04518852 2024-06-25
TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC
Sichuan Cancer Hospital and Research Institute
Phase 2 Completed
NCT00813293 2023-06-13
Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer
Beth Israel Deaconess Medical Center
Phase 2 Completed
NCT02575339 2022-07-26
MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma
Big Ten Cancer Research Consortium
Phase 1/2 Terminated
NCT00867321 2022-04-19
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Alliance for Clinical Trials in Oncology
Phase 1/2 Completed
NCT02292173 2021-06-10
Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT01032850 2021-06-02
Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT03971201 2021-04-14
A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion
White Plains Hospital
Phase 2 Unknown
NCT01033240 2021-04-08
CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer
Daiichi Sankyo
Phase 2 Completed
NCT02988440 2020-12-19
Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients
Novartis
Phase 1 Completed
NCT03164382 2020-12-16
Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil/Leucovorin Versus Sorafenib in Advanced Hepatocellular Carcinoma
Sun Yat-sen University
Phase 3 Completed
NCT01264705 2020-11-12
Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer
University of Texas Southwestern Medical Center
Phase 1/2 Completed
NCT02069145 2020-08-11
Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
Mereo BioPharma
Phase 1 Completed
NCT02989870 2020-06-05
Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Withdrawn
NCT01775501 2020-04-22
Sorafenib + mFOLFOX for Hepatocellular Carcinoma
Massachusetts General Hospital
Phase 2 Completed
NCT01075555 2020-03-30
Sorafenib Tosylate With or Without Pravastatin in Treating Patients With Liver Cancer and Cirrhosis
Federation Francophone de Cancerologie Digestive
Phase 3 Completed
NCT01497444 2020-02-06
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
Alliance for Clinical Trials in Oncology
Phase 1 Completed
NCT02288507 2019-11-08
Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer
University of Hawaii
Phase 1 Withdrawn
NCT04069949 2019-10-25
STUHCCPVTT
Sichuan University
Phase 1/2 Unknown
NCT01075113 2019-08-20
Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer
Virginia Commonwealth University
Phase 1 Completed
NCT00941967 2019-07-10
Sorafenib With or Without Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Liver Cancer
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 2 Completed
NCT01005199 2019-05-15
Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer
Swiss Cancer Institute
Phase 2 Completed
NCT01008917 2019-05-09
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
University of California, San Francisco
Phase 1 Completed
NCT01498952 2019-02-19
MEDI-573-1028
MedImmune LLC
Phase 1 Completed
NCT01306058 2019-01-23
Sorafenib and TRC105 in Hepatocellular Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00692770 2018-08-08
STORM
Bayer
Phase 3 Completed
NCT00906373 2018-06-04
A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver
Eli Lilly and Company
Phase 2 Completed
NCT01932385 2018-02-14
Sorafenib in Liver Function Impaired Advanced Hepatocellular Carcinoma
Qingdao Central Hospital
Phase 2/3 Completed
NCT01011010 2018-01-05
Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
UNC Lineberger Comprehensive Cancer Center
Phase 1 Completed
NCT01334710 2017-11-21
A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer
Emory University
Phase 2 Terminated
NCT01217034 2017-10-31
TACTICS
Kindai University
Phase 2 Unknown
NCT01901692 2017-09-18
START
Asan Medical Center
Phase 2/3 Completed
NCT00881751 2017-09-11
Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer
Medical University of South Carolina
Phase 2 Completed
NCT01005875 2017-05-10
RAD 0901
University of Alabama at Birmingham
Phase NA Terminated
NCT01849588 2017-04-19
HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC)
Massachusetts General Hospital
Phase 4 Terminated
NCT02323906 2017-03-20
Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer
Celgene
Phase 1 Terminated
NCT01232296 2015-12-04
A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment
Novartis
Phase 2 Completed
NCT00997022 2015-08-10
Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients
Columbia University
Phase 1 Completed
NCT01029418 2015-04-16
AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma
National Cancer Centre, Singapore
Phase 1/2 Terminated
NCT01203787 2015-03-05
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
University of Florida
Phase 4 Completed
NCT00105443 2014-10-31
SHARP
Bayer
Phase 3 Completed
NCT00108953 2014-10-31
A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma
Bayer
Phase 2 Completed
NCT00044512 2014-04-16
A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma
Bayer
Phase 2 Completed
NCT00398814 2014-02-19
Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers
AEterna Zentaris
Phase 1 Completed
NCT00949182 2014-01-14
Sorafenib Tosylate Before and After Hepatic Arterial Chemoembolization With Doxorubicin Hydrochloride and Mitomycin C in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery
Rutgers, The State University of New Jersey
Phase 2 Completed
NCT00494299 2013-12-20
Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)
Bayer
Phase 3 Completed
NCT00956436 2013-09-16
Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)
Biogen
Phase 1 Completed